Genscript Biotech Corporation
1548
Rang in Aktien
#2135
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Aktienkurs
$4.28
Marktkapitalisierung
$9.61B
Veränderung (1 Tag)
0.36%
Veränderung (1 Jahr)
107.31%
Land
HK
Handel Genscript Biotech Corporation (1548)
Kategorie
Healthcare
EPS für Genscript Biotech Corporation (1548)
EPS zum June 2026 TTM: $-0.30
Laut den aktuellen Finanzberichten und dem Aktienkurs von Genscript Biotech Corporation beträgt das aktuelle EPS des Unternehmens (TTM) $-0.30. Am Ende des Jahres 2023 betrug das EPS $-0.05 ein Rückgang im Vergleich zu dem EPS von 2022, das $-0.11 betrug.
EPS-Verlauf von Genscript Biotech Corporation von 2013 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $-0.30 | 900.00% |
| 2024 | $-0.03 | -31.57% |
| 2023 | $-0.05 | -58.82% |
| 2022 | $-0.11 | -38.89% |
| 2021 | $-0.18 | 63.64% |
| 2020 | $-0.11 | 110.33% |
| 2019 | $-0.05 | -543.22% |
| 2018 | $0.01 | -22.37% |
| 2017 | $0.02 | -3.18% |
| 2016 | $0.02 | 6.80% |
| 2015 | $0.01 | 182.69% |
| 2014 | $0.01 | 36.84% |
| 2013 | 0.00 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | -5,873.33% |
US
|
|
| $-7.98 | 2,560.00% |
US
|
|
| $-5.29 | 1,663.33% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -9,346.67% |
NL
|
